Personalis (NASDAQ:PSNL) Given New $7.00 Price Target at Needham & Company LLC

Personalis (NASDAQ:PSNL) had its target price lowered by equities research analysts at Needham & Company LLC from $7.25 to $7.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target would indicate a potential upside of 65.09% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Lake Street Capital increased their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright decreased their price objective on shares of Personalis from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, January 27th.

Personalis Stock Down 5.4 %

Personalis stock opened at $4.24 on Friday. Personalis has a 52-week low of $1.13 and a 52-week high of $7.20. The company has a market cap of $299.55 million, a P/E ratio of -2.52 and a beta of 1.73. The business has a 50-day simple moving average of $5.43 and a two-hundred day simple moving average of $5.04.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Research analysts anticipate that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Personalis during the 4th quarter valued at approximately $28,000. JPMorgan Chase & Co. grew its stake in Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after acquiring an additional 5,654 shares in the last quarter. Olympiad Research LP bought a new stake in Personalis in the 4th quarter valued at $59,000. Alpine Global Management LLC purchased a new stake in Personalis in the 4th quarter worth $60,000. Finally, SG Americas Securities LLC bought a new position in shares of Personalis during the 4th quarter valued at about $63,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.